Skip to main content
editorial
. 2015 Oct 1;18(1):15–22. doi: 10.1208/s12248-015-9830-9

Table III.

Similarities and Differences in the Minimum Number of Time Points Required for an f 2 Calculation

Country Minimum number of time points
China (20) A minimum of three time points (zero excluded) until drugs undergo more than 90% dissolution or reaches dissolution platform.
Europe (5), Australia (17), Russia (5), Turkey (27) A minimum of three time points (zero excluded).
South Africa (28), Thailand (26), United States (14) A minimum of three time points.
India (21) Suitably spaced time points to provide a profile for each batch (e.g., 10, 20, 30 min) to achieve virtually complete dissolution.
Canada (19) Adequate sampling should be performed until either 90% of drug from the drug product is dissolved or an asymptote is reached.
Mexico (25) At least five sampling points. Only two points will be on the plateau of the curve and the other three will be distributed between the ascending stage and the inflection stage.
Brazil (18) A minimum of five time points (zero excluded).
Japan (6,23,24)

•% Dissolution ≥85% in 15–30 min: three time points.

•% Dissolution is ≥85% at 120 min in pH 1.2 and 360 min in other media: four time points.

•% Dissolution is 50–85% between 30 and 120 min in pH 1.2 and 30–360 min in other media: eight time points.

•% Disso <50% between 30 and 120 min in pH 1.2 and 30–360 min in other media: eight time points.

South Korea (29)

•If the mean dissolution rate of reference drug is NLT 85% within 15 ~ 30 min: 15, 30, 45 min (three time points).

•If the mean dissolution rate of reference drug is not less than 85% after 30 min but within specified test time: Ta/4, 2Ta/4, 3Ta/4. Ta, where Ta is the time point when the mean dissolution rate of reference drug is approx 85%.

•If the mean dissolution rate of reference drug is less than 85% within the specified test time: Ta/4, 2Ta/4, 3Ta/4. Ta, where Ta is the time point when the mean dissolution rate of reference drug is approx 85% with the test time.